Debate grows over HHS policy allowing limited compounding of six unapproved peptides

Recent coverage centers on an HHS interim enforcement-discretion policy announced in late October 2026. It says federal authorities do not intend to take enforcement action against qualifying compounders using six peptides—BPC-157, epitalon, KPV, MOTS-c, semax, and TB-500—while FDA develops the relevant compounding rules. This is not FDA approval of those drugs.

HHS argues the policy could steer patients away from research-use-only products sold by foreign suppliers and toward compounding subject to conditions such as patient-specific prescriptions, ingredient testing, sourcing requirements, and reporting serious adverse events.

Critics, including FDA scientific staff, warn that the peptides lack adequate evidence of safety and effectiveness and may have unresolved purity, contamination, and immune-reaction risks. Reporting also describes gaps in human data for several proposed uses.

The drug-development concern is that wider commercial access before rigorous trials could reduce incentives to fund clinical research and blur the distinction between compounded products and FDA-approved medicines.

Important caveat:
compounded drugs are not FDA-approved, and FDA does not review them for safety, effectiveness, or quality before they are marketed. The policy is temporary enforcement discretion, not a finding that the peptides are safe.